{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:10:57Z","timestamp":1765995057202,"version":"3.40.5"},"reference-count":76,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease Markers"],"published-print":{"date-parts":[[2022,9,14]]},"abstract":"<jats:p>Background. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) leads to significant morbidity. Other coadministered drugs may modulate the risk for BRONJ. The present study aimed to leverage bioinformatic data mining to identify drugs that potentially modulate the risk of BRONJ in cancer. Methods. A GEO gene expression dataset of peripheral blood mononuclear cells related to BRONJ in multiple myeloma patients was downloaded, and differentially expressed genes (DEGs) in patients with BRONJ versus those without BRONJ were identified. A protein-protein interaction network of the DEGs was constructed using experimentally validated interactions in the STRING database. Overrepresented Gene Ontology (GO) molecular function terms and KEGG pathways in the network were analysed. Network topology was determined, and \u2018hub genes\u2019 with degree \u22652 in the network were identified. Known drug targets of the hub genes were mined from the \u2018drug gene interaction database\u2019 (DGIdb) and labelled as candidate drugs affecting the risk of BRONJ. Results. 751 annotated DEGs (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi mathvariant=\"normal\">log<\/a:mi>\n                        <a:mtext>\u2009<\/a:mtext>\n                        <a:mtext>FC<\/a:mtext>\n                        <a:mo>\u2265<\/a:mo>\n                        <a:mn>1.5<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>, <jats:inline-formula>\n                     <d:math xmlns:d=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <d:mi>p<\/d:mi>\n                        <d:mo>&lt;<\/d:mo>\n                        <d:mn>0.05<\/d:mn>\n                     <\/d:math>\n                  <\/jats:inline-formula>) were obtained from the microarray gene expression dataset GSE7116. A PPI network with 633 nodes and 168 edges was constructed. Data mining for drugs interacting with 49 gene nodes was performed. 37 drug interactions were found for 9 of the hub genes including TBP, TAF1, PPP2CA, PRPF31, CASP8, UQCRB, ACTR2, CFLAR, and FAS. Interactions were found for several established and novel anticancer chemotherapeutic, kinase inhibitor, caspase inhibitor, antiangiogenic, and immunomodulatory agents. Aspirin, metformin, atrovastatin, thrombin, androgen and antiandrogen drugs, progesterone, Vitamin D, and Ginsengoside 20(S)-Protopanaxadiol were also documented. Conclusions. A bioinformatic data mining strategy identified several anticancer, immunomodulator, and other candidate drugs that may affect the risk of BRONJ in cancer patients.<\/jats:p>","DOI":"10.1155\/2022\/3348480","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T02:20:38Z","timestamp":1663208438000},"page":"1-10","source":"Crossref","is-referenced-by-count":5,"title":["Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-8877","authenticated-orcid":true,"given":"Jinpeng","family":"Zhuang","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin 150081, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Zu","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin 150081, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changlong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin 150081, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin 150081, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyu","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin 150081, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-8410","authenticated-orcid":true,"given":"Yongbin","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin 150081, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3890"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/637976"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200007000-00017"},{"issue":"3","key":"4","first-page":"288","article-title":"Use of bisphosphonates in chronic kidney disease","volume":"30","author":"J.-V. Torregrosa","year":"2010","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2008.12.006"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1007\/s005200100292"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05357-5"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S85496"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2018.04.009"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2006.11.003"},{"issue":"1","key":"12","first-page":"37","article-title":"Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"4","author":"S. L. Ruggiero","year":"2007","journal-title":"Clinical Cases in Mineral and Bone Metabolism"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1177\/0022034510397196"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2015.50964"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.30881\/jdsomr.00015"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.01.003"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-010-0162-7"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.33448\/rsd-v11i4.21577"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204762"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.05.001"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4501-x"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1111\/cid.12569"},{"issue":"4","key":"23","first-page":"159","article-title":"Immune-related expression profiles of bisphosphonates-related osteonecrosis of the jaw in multiple myeloma","volume":"76","author":"J. He","year":"2021","journal-title":"Die Pharmazie-An International Journal of Pharmaceutical Sciences"},{"key":"24","first-page":"3591","volume-title":"Clinical, radiographic, and biomarker characterization of multiple myeloma patients with bisphosphonate associated osteonecrosis of the jaw","author":"N. Raje","year":"2006"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1131"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021800"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2450"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-1-23"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00045"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.050047"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4032-1"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831050-00001"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn653"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2011.08.011"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00283-0"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm370"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.2186\/jpr.JPR_D_20_00027"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.34172\/jlms.2020.78"},{"issue":"4","key":"39","first-page":"473","article-title":"Pharmacological caspase inhibitors: research towards therapeutic perspectives","volume":"66","author":"J. Kudelova","year":"2015","journal-title":"Journal of physiology and pharmacology: an official journal of the Polish Physiological Society"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107341"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30199"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2577"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1369\/0022155417739283"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1111\/jre.12798"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.2174\/1570163812666150602144310"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.9.8.11264"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2027573"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.628332"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.08.036"},{"key":"50","doi-asserted-by":"publisher","DOI":"10.3858\/emm.2011.43.3.016"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.69"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01634-0"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3903-5"},{"key":"54","first-page":"5551","volume-title":"Tumor responses and preliminary survival data in a phase II trial of ofranergene obadenovec (VB-111) combined with paclitaxel in patients with recurrent platinum resistant ovarian cancer","author":"R. T. Penson","year":"2016"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.02.014"},{"key":"56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164173"},{"key":"57","first-page":"e15186","volume-title":"Effect of idronoxil combined with cisplatin on refractory immune responses in nasopharyngeal carcinoma","author":"N.-W. Kam","year":"2020"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S216675"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.04.048"},{"key":"60","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2022.05.003"},{"key":"61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126672"},{"key":"62","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005332"},{"key":"63","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14681"},{"key":"64","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000047"},{"key":"65","doi-asserted-by":"publisher","DOI":"10.2186\/jpr.JPOR_2019_629"},{"key":"66","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102796"},{"key":"67","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-200105000-00022"},{"key":"68","doi-asserted-by":"publisher","DOI":"10.1002\/JPER.21-0294"},{"key":"69","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0747-y"},{"key":"70","doi-asserted-by":"publisher","DOI":"10.1039\/C7BM00975E"},{"key":"71","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2438"},{"key":"72","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313709200"},{"key":"73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.606043"},{"issue":"7","key":"74","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"M. A. Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"75","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b16-00041"},{"key":"76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118084"}],"container-title":["Disease Markers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/3348480.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/3348480.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2022\/3348480.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T02:20:51Z","timestamp":1663208451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/dm\/2022\/3348480\/"}},"subtitle":[],"editor":[{"given":"Aneesha","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":76,"alternative-id":["3348480","3348480"],"URL":"https:\/\/doi.org\/10.1155\/2022\/3348480","relation":{},"ISSN":["1875-8630","0278-0240"],"issn-type":[{"type":"electronic","value":"1875-8630"},{"type":"print","value":"0278-0240"}],"subject":[],"published":{"date-parts":[[2022,9,14]]}}}